Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
63 studies found for:    "VLDLR-associated cerebellar hypoplasia" [DISEASE] OR "Cerebellar Ataxia" [DISEASE] OR NCT00041600 [ID-NUMBER]
Show Display Options
Rank Status Study
21 Unknown  Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
Conditions: Spinocerebellar Ataxias;   Spastic Paraplegias
Intervention:
22 Completed Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)
Condition: Hereditary Ataxia
Intervention:
23 Recruiting The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease
Condition: Machado Joseph Disease (SCA3)
Intervention: Device: Deep TMS
24 Completed
Has Results
Dalfampridine and Gait in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxias Type 1;   Spinocerebellar Ataxias Type 2;   Spinocerebellar Ataxias Type 3;   Spinocerebellar Ataxias Type 6
Interventions: Drug: Dalfampridine;   Drug: Placebo
25 Unknown  Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
Conditions: Ataxia Telangiectasia;   Growth Failure
Intervention: Drug: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
26 Completed Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
Condition: SPINOCEREBELLAR ATAXIA 2
Intervention: Drug: LITHIUM CARBONATE
27 Recruiting Parkinsonism in Spinocerebellar Ataxia Type 6
Condition: Spinocerebellar Ataxia Type 6
Intervention:
28 Recruiting A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose;   Drug: Placebo
29 Recruiting An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
30 Withdrawn Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: Placebo;   Drug: Sodium Phenylbutyrate
31 Unknown  The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally
Condition: Ataxia Telangiectasia
Intervention:
32 Recruiting Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
Condition: Machado-Joseph Disease / Spinocerebellar Ataxia 3
Intervention: Drug: Cabaletta for IV infusion once weekly during 24 weeks
33 Completed Study for Treatment of Cancer in Children With Ataxia-telangiectasia
Condition: Ataxia-Telangiectasia
Interventions: Drug: vinblastine, vincristine, prednisone, daunorubicin;   Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase;   Drug: etoposide, cytarabine, mercaptopurine;   Drug: dexamethasone, procarbazine;   Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
34 Not yet recruiting Pancreatic Cancer Screening of High-Risk Residents of Arkansas
Conditions: Pancreatic Neoplasms;   Peutz-Jegher's Syndrome;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Ataxia Telangiectasia;   Familial Atypical Mole-Malignant Melanoma Syndrome;   Colorectal Neoplasms, Hereditary Nonpolyposis;   Hereditary Pancreatitis
Intervention: Other: Pancreatic Cancer Screening
35 Recruiting Machado-Joseph Disease in Israel
Condition: Spinocerebellar Ataxia 3
Intervention:
36 Completed Body Composition and Hormonal Status in Ataxia Telangiectasia
Condition: Ataxia Telangiectasia
Interventions: Procedure: bioelectrical impedance analysis;   Procedure: blood draw
37 Completed Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Biological: IVIG
38 Completed A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373;   Drug: Placebo
39 Unknown  Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients
Condition: Ataxia Telangiectasia
Interventions: Biological: Prevenar® (7-valent pneumococcal conjugate vaccine);   Biological: Pneumovax® (pneumococcal polysaccharide vaccine)
40 Completed Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Intervention: Drug: KPS-0373

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years